Virion Therapeutics, LLC and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.
